» Articles » PMID: 26105620

Molecular Mechanisms Underlying HBsAg Negativity in Occult HBV Infection

Overview
Publisher Springer
Date 2015 Jun 25
PMID 26105620
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Although genomic detection is considered the gold standard test on HBV infection identification, the HBsAg investigation is still the most frequent clinical laboratory request to diagnose HBV infection in activity. However, the non-detection of HBsAg in the bloodstream of chronic or acutely infected individuals has been a phenomenon often observed in clinical practice, despite the high sensitivity and specificity of screening assays standardized commercially and adopted in routine. The expansion of knowledge about the hepatitis B virus biology (replication/life cycle, genetic variability/mutability/heterogeneity), their biochemical and immunological properties (antigenicity and immunogenicity), in turn, has allowed to elucidate some mechanisms that may explain the occurrence of this phenomenon. Therefore, the negativity for HBsAg during the acute or chronic infection course may become a fragile or at least questionable result. This manuscript discusses some mechanisms that could explain the negativity for HBsAg in a serological profile of individuals with HBV infection in activity, or factors that could compromise its detection in the bloodstream during HBV infection.

Citing Articles

Increasing Prevalence of Occult HBV Infection in Adults Vaccinated Against Hepatitis B at Birth.

Zhong G, Jiang Z, Wang X, Chen Q, Zhang L, Hu L Vaccines (Basel). 2025; 13(2).

PMID: 40006721 PMC: 11860204. DOI: 10.3390/vaccines13020174.


Detection of hepatitis B virus surface antigen, IgM and IgG antibodies to hepatitis B virus core antigen in the clinical classification and epidemiological surveillance of HBV infection.

de Almeida Ponde R Mol Biol Rep. 2025; 52(1):195.

PMID: 39903324 DOI: 10.1007/s11033-025-10278-9.


An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination.

Delghandi S, Raoufinia R, Shahtahmasbi S, Meshkat Z, Gouklani H, Gholoobi A Heliyon. 2024; 10(17):e37097.

PMID: 39281486 PMC: 11402251. DOI: 10.1016/j.heliyon.2024.e37097.


Molecular and Serological Characterization of Hepatitis B Virus (HBV)-Positive Samples with Very Low or Undetectable Levels of HBV Surface Antigen.

Kuhns M, Holzmayer V, Anderson M, McNamara A, Sauleda S, Mbanya D Viruses. 2021; 13(10).

PMID: 34696483 PMC: 8537069. DOI: 10.3390/v13102053.


Detection of Q129H Immune Escape Mutation in Apparently Healthy Hepatitis B Virus Carriers in Southwestern Nigeria.

Adesina O, Akanbi O, Opaleye O, Japhet M, Wang B, Oluyege A Viruses. 2021; 13(7).

PMID: 34210073 PMC: 8310067. DOI: 10.3390/v13071273.


References
1.
Stramer S, Zou S, Notari E, Foster G, Krysztof D, Musavi F . Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?. Transfusion. 2011; 52(2):440-6. DOI: 10.1111/j.1537-2995.2011.03283.x. View

2.
Gerlich W, THOMSSEN R . Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume. Dev Biol Stand. 1975; 30:78-87. View

3.
Chaudhuri V, Tayal R, Nayak B, Acharya S, Panda S . Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology. 2004; 127(5):1356-71. DOI: 10.1053/j.gastro.2004.08.003. View

4.
Kramvis A, Kew M . The core promoter of hepatitis B virus. J Viral Hepat. 1999; 6(6):415-27. DOI: 10.1046/j.1365-2893.1999.00189.x. View

5.
Seeger C, Mason W . Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1):51-68. PMC: 98986. DOI: 10.1128/MMBR.64.1.51-68.2000. View